High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma
Martin Lang(National Institutes of Health), W. Marston Linehan(National Cancer Institute)
Cited by 18
Related Papers
Metabolic Reprogramming for Producing Energy and Reducing Power in Fumarate Hydratase Null Cells from Hereditary Leiomyomatosis Renal Cell Carcinoma
|PLoS ONE|2013|110
Mitochondrial DNA mutations distinguish bilateral multifocal renal oncocytomas from familial Birt–Hogg–Dubé tumors
|Modern Pathology|2015|30